Related Experiment Videos
CCK-B antagonists in the control of anxiety and gastric acid secretion
1Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex, U.K.
Progress in Medicinal Chemistry
|June 9, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Discovery of ONO-8590580: A novel, potent and selective GABAA α5 negative allosteric modulator for the treatment of cognitive disorders.
Bioorganic & medicinal chemistry letters·2020
Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA alpha5-subtype inverse agonist.
Xenobiotica; the fate of foreign compounds in biological systems·2006
3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Journal of medicinal chemistry·1999
Prosthetic rehabilitation of patients with advanced nonmelanoma skin cancer.
Clinics in plastic surgery·1997
The rise of AlphaFold in drug design.
Progress in medicinal chemistry·2025
Drug design strategies for the selective targeting of lung, liver and kidney.
Progress in medicinal chemistry·2025
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives.
Progress in medicinal chemistry·2024
Another decade of antimalarial drug discovery: New targets, tools and molecules.
Progress in medicinal chemistry·2024
Harnessing conformational drivers in drug design.
Progress in medicinal chemistry·2024
Biophysical screening and characterisation in medicinal chemistry.
Progress in medicinal chemistry·2023
Cannabinoid modulation of central amygdala population dynamics during threat investigation.
Nature communications·2026
Development and assessment of an artificial intelligence-based tool for scoring lesion severity in generalized pustular psoriasis clinical images.
JID innovations : skin science from molecules to population health·2026
Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States, 2025.
American journal of public health·2026